107 related articles for article (PubMed ID: 11710450)
1. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.
Hwang L; Orengo I
Cutis; 2001 Oct; 68(4):287-8. PubMed ID: 11710450
[No Abstract] [Full Text] [Related]
2. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
[TBL] [Abstract][Full Text] [Related]
3. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.
Drago F; Brusati C; Mancardi G; Murialdo A; Rebora A
Arch Dermatol; 1999 Oct; 135(10):1277-8. PubMed ID: 10522686
[No Abstract] [Full Text] [Related]
4. Glatiramer acetate for relapsing multiple sclerosis.
Med Lett Drugs Ther; 1997 Jul; 39(1004):61-2. PubMed ID: 9217693
[No Abstract] [Full Text] [Related]
5. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
Edgar CM; Brunet DG; Fenton P; McBride EV; Green P
Can J Neurol Sci; 2004 Feb; 31(1):58-63. PubMed ID: 15038472
[TBL] [Abstract][Full Text] [Related]
6. [Embolia cutis medicamentosa (Nicolau syndrome) after glatiramer acetate injection].
Martínez-Morán C; Espinosa-Lara P; Nájera L; Romero-Maté A; Córdoba S; Hernández-Núñez A; Borbujo J
Actas Dermosifiliogr; 2011 Nov; 102(9):742-4. PubMed ID: 21741603
[No Abstract] [Full Text] [Related]
7. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
Soós N; Shakery K; Mrowietz U
Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
[TBL] [Abstract][Full Text] [Related]
8. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study.
Soares Almeida LM; Requena L; Kutzner H; Angulo J; de Sa J; Pignatelli J
J Am Acad Dermatol; 2006 Dec; 55(6):968-74. PubMed ID: 17097393
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
Racke MK; Lovett-Racke AE; Karandikar NJ
Neurology; 2010 Jan; 74 Suppl 1():S25-30. PubMed ID: 20038760
[TBL] [Abstract][Full Text] [Related]
10. Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site.
Rubio Fernández D; Rodríguez Del Canto C; Marcos Galán V; Falcón N; Edreira H; Sevane Fernández L; Francoli Martínez P; Sánchez-De la Rosa R
Adv Ther; 2012 Mar; 29(3):267-75. PubMed ID: 22382874
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092
[No Abstract] [Full Text] [Related]
12. Ischemic skin necrosis caused by glatiramer acetate in multiple sclerosis patients.
Samões R; Carvalho S; Alves R; Torres T; Silva AM
Eur J Dermatol; 2014; 24(3):411-2. PubMed ID: 24751754
[No Abstract] [Full Text] [Related]
13. Nicolau syndrome following subcutaneous glatiramer-acetate injection.
Koller S; Kränke B
J Am Acad Dermatol; 2011 Feb; 64(2):e16-7. PubMed ID: 21238820
[No Abstract] [Full Text] [Related]
14. [Glatiramer acetate in patients with clinically isolated multiple sclerosis syndrome: PreCISe study].
Diener HC; Nitschmann S
Internist (Berl); 2010 Jun; 51(6):793-4. PubMed ID: 20336274
[No Abstract] [Full Text] [Related]
15. The effectiveness of glatiramer acetate in clinical practice: an observational study.
Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
[TBL] [Abstract][Full Text] [Related]
16. Systemic reaction to glatiramer acetate.
Bayerl C; Bohland P; Jung EG
Contact Dermatitis; 2000 Jul; 43(1):62-3. PubMed ID: 10902605
[No Abstract] [Full Text] [Related]
17. Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate.
Lebrun C; Mondot L; Bertagna M; Calleja A; Cohen M
Clin Neurol Neurosurg; 2011 Nov; 113(9):721-4. PubMed ID: 21839580
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer: cutaneous necrosis.
Prescrire Int; 2007 Dec; 16(92):251. PubMed ID: 18095390
[No Abstract] [Full Text] [Related]
19. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
20. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
